MDS Program

About Aptadir

Aptadir is a preclinical-stage biotech leveraging a novel RNA-based platform to target DNA methylation, a key epigenetic driver of disease. The company's technology offers two modalities: global DNMT1 inhibition (aptaDiR) and locus-specific targeting (captaDiR), aiming for greater specificity and reduced toxicity compared to existing epigenetic drugs. With a seasoned leadership team and scientific founders from prestigious institutions, Aptadir is positioned to address high-need areas in oncology and rare diseases. The company is currently in the preclinical research phase, building its pipeline for untreatable cancers.

Therapeutic Areas